SciELO - Scientific Electronic Library Online

vol.62 número3Use of health and nutritional endorsements in unhealthy food and beverages in Mexico: opportunity to avoid misleading informationDosis letal y diagnóstica de carbamatos para Centruroides limpidus Karsch 1879 (Scorpiones: Buthidae), de Morelos, México índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • No hay artículos similaresSimilares en SciELO


Salud Pública de México

versión impresa ISSN 0036-3634

Salud pública Méx vol.62 no.3 Cuernavaca may./jun. 2020  Epub 16-Mayo-2022 

Cartas al Editor

RENACED-DT1: A National Type 1 Diabetes Registry Initiative in Mexico

Raquel N. Faradji(1  ,2) 

Marisol Valenzuela-Lara(3) 

Maricela Vidrio-Velázquez(4) 

Alicia E. Yepez-Rodríguez(5) 

Guillermo González-Galvez(6) 

María E.  Sainz de la Maza-Viadero(1)  on behalf of RENACED-DT1 Research Group

(1)Clinica EnDi. Mexico City, Mexico.

(2)Centro Médico ABC. Mexico City, Mexico.

(3)Centro Nacional para la Prevención y el Control del VIH y el Sida. Mexico City, Mexico.

(4)Instituto Mexicano del Seguro Social, Hospital General Regional núm. 110. Guadalajara, Mexico.

(5)Corporativo Hospital Satélite, Internal Medicine and Endocrinology. Mexico City, Mexico.

(6)Instituto Jalisciense de Investigación en Diabetes y Obesidad. Guadalajara, Mexico.

Dear editor: Type 1 diabetes (T1D) is one of the most common chronic diseases in childhood, it is not preven-table, and if not treated with insulin, is mortal. Suboptimal insulin treatment increases the risk of complications.1

According to Mexican Institute for Social Security (Instituto Mexicano del Seguro Social, IMSS), the T1D inci- dence in <19 years-old increased from 3.4 to 6.2/100 000 between 2000 and 2010.2 The 2017 morbidity yearbook reported 5.45 new cases/100 000. The prevalence of T1D in Mexico is unk- nown and there is scare information regarding diagnosis, treatment and follow-up. International registries3 have improved disease understanding, treatment practices and public health policies. These have documented increased incidence and prevalence of T1D in the last 20 years; none of them include Latin-American populations. The few studies available in Mexico, address T1D in childhood and adolescence,4 but no long-term outcomes.3

To address this unmet need, a group of T1D patients and physicians, developed an online T1D registry in Mexico for longitudinal follow-up: National Registry of Patients with Type 1 Diabetes (Registro Nacional de Pacientes con Diabetes Tipo 1, RENACED-DT1).5 This represents the first longitudinal registry in Mexico. It is endorsed by the Mexican Society of Nutrition and Endocrinology (Sociedad Mexicana de Nutrición y Endocrinología). We present an exploratory analysis of 965 patients registered from 7/2014- 1/2018: females 61%, current median age 21 years, median diagnosis age 11 years (figure 1a), median disease duration at enrollment 8.2 years (figure 1b); 58% in the private and 42% in the public sectors; 54% required hospitalization at diagnosis, 41% presented with diabetic ketoacidosis and 9% were treated at an intensive care unit; 81% were diagnosed after the year 2000 (figure 1c).

Figure 1 Selected characteristics of cases registered in the RENACED type 1 diabetes registry in Mexico. 1a. Age at diagnosis. 1b. Type 1 diabetes duration in years. 1c. Year of type 1 diabetes diagnosis 

Most frequent treatment is basal- bolus with insulin analogues (61%); 21% use insulin-pumps and 9% use continuous glucose monitoring, the latter mostly in the private sector. Mean glycated hemoglobin A1c at last follow-up was 8.7±2.1% (72±23 mmol/mol). Forty four percent were overweight or obese. With longer dia- betes duration, higher frequency of chronic complications was observed. A limitation to date is the insufficient public sector representation.

Mexican government funds should be available to optimally treat T1D patients permanently (par-ticularly those recently diagnosed), to decrease the incidence of compli- cations, improve quality of life and productivity.

RENACED-DT1 registry will help increase understanding the T1D reality in Mexico, to boost advocacy efforts to change public health policy and improve universal access to state- of-the-art therapy.


The authors would like to ack- nowledge all the patients that chose to participate in the registry and the RENACED-DT1 Research Group (


Doubova SV, Ferreira-Hermosillo A, Pérez- Cuevas R, Barsoe C, Gryzbowski-gainza E, Valencia JE. Socio-demographic and clinical cha- racteristics of type 1 diabetes patients associated with emergency room visits and hospitalizations in Mexico. BMC Health Serv Res. 2018;18:602-12. [ Links ]

Gomez-Diaz RA, Perez-Perez G, Hernandez- Cuesta IT, Rodriguez-Garcia JD, Guerrero-Lopez R, Aguilar-Salinas CA,Wacher NH. Incidence of type 1 diabetes in Mexico: Data from an institutional register 2000-2010. Diabetes Care. 2012;35(11):2450. [ Links ]

Beck RW,Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA.The T1D exchange clinic registry. J Clin Endocrinol Metab. 2012;97(12):4383-9. [ Links ]

Gomez-Diaz R, Garibay-Nieto N,Wacher- Rodarte N, Aguilar-Salinas C. Epidemiology of Type 1 Diabetes in Latin America. Curr Diabetes Rev. 2014;10(2):75-85. [ Links ]

RENACED DT1. Registro Nacional de Pacientes con Diabetes Tipo 1. 2014. Available from: ]

Creative Commons License Este es un artículo publicado en acceso abierto bajo una licencia Creative Commons